Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SENSIPAR vs LANOXICAPS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcimimetic agent that allosterically modulates the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.
Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.
Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,Hypercalcemia in patients with parathyroid carcinoma,Severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation (rate control)
30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target i PTH reduction.
0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.
The terminal elimination half-life of cinacalcet is approximately 30 to 40 hours in patients with normal renal function, supporting once-daily dosing. Steady-state concentrations are achieved within 7 days.
Terminal elimination half-life is approximately 5-7 days (120-168 hours) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Hepatic via CYP3A4, CYP2D6, CYP1A2; major metabolites are inactive.
Primarily renal excretion as unchanged drug; minor hepatic metabolism via CYP3A4 and glucuronidation.
Renal excretion of unchanged drug and metabolites accounts for approximately 84% of the administered dose; fecal excretion accounts for approximately 11%. The primary metabolic pathway is CYP3A4-mediated oxidation, followed by glucuronidation.
Digitoxin is primarily excreted via the kidneys (approx. 70-80%) as unchanged drug and metabolites; the remainder undergoes biliary/fecal elimination (approx. 20-30%).
Cinacalcet is approximately 93 to 97% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
Digitoxin is approximately 90-97% bound to serum proteins, primarily albumin.
The volume of distribution is approximately 1000 L (about 14 L/kg in a 70 kg individual), indicating extensive tissue distribution.
Volume of distribution is approximately 0.6 L/kg, indicating extensive tissue binding and distribution; the large Vd reflects accumulation in tissues like myocardium and skeletal muscle.
Oral bioavailability is approximately 20 to 25% due to first-pass metabolism; administration with food increases bioavailability by approximately 50% compared to fasting.
Oral bioavailability is virtually 100% (90-100%) for Lanoxicaps (digitoxin), with consistent absorption from the gastrointestinal tract.
No dose adjustment required for mild to moderate renal impairment (Cr Cl >= 30 m L/min). Not recommended for patients with severe renal impairment (Cr Cl < 30 m L/min) due to lack of data.
For e GFR <50 m L/min, reduce dose by 50% or extend dosing interval: e GFR 35-50 m L/min: 0.125 mg every 24-48 hours; e GFR 10-34 m L/min: 0.125 mg every 48-72 hours; e GFR <10 m L/min: 0.125 mg every 72-96 hours.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Use with caution in severe hepatic impairment (Child-Pugh Class C) with no specific dose recommendations.
Severe hepatic impairment (Child-Pugh class C) requires dose reduction by 50-75%; monitor digoxin levels. Avoid in fulminant hepatitis.
Safety and effectiveness in pediatric patients have not been established.
Neonates: 4-6 mcg/kg/day; Infants: 6-10 mcg/kg/day; Children 1-5 years: 10-15 mcg/kg/day; Children 6-12 years: 8-10 mcg/kg/day; Adolescents: 3-5 mcg/kg/day. All doses given orally.
No specific dose adjustment; dosing should be based on renal function. Elderly patients may have decreased renal function; monitor serum calcium and i PTH levels closely.
Start at lower dose (0.0625-0.125 mg daily) due to reduced renal function and lean body mass; monitor serum creatinine and digoxin levels.
None.
Toxicity: Narrow therapeutic index; monitor serum levels; avoid in patients with ventricular fibrillation or outflow obstruction.
Hypocalcemia: monitor serum calcium, especially during initiation and dose titration,Seizures: risk due to hypocalcemia,QT prolongation: caution in patients with history of QT interval prolongation or on concurrent QT-prolonging drugs,Hypotension: possible during dialysis use,Adynamic bone disease: potential with oversuppression of PTH
Monitor for digitalis toxicity (anorexia, nausea, visual disturbances, arrhythmias). Adjust dose in renal impairment, hypokalemia, hypomagnesemia, hypercalcemia, and hypothyroidism.
Hypocalcemia (serum calcium < 8.4 mg/d L)
Ventricular fibrillation,Hypersensitivity to digitalis glycosides,Wolff-Parkinson-White syndrome with atrial fibrillation,Second- or third-degree AV block (without pacemaker),Hypertrophic obstructive cardiomyopathy
SENSIPAR should be taken with food or shortly after a meal to enhance absorption. No specific foods are contraindicated, but avoid high-calcium meals immediately before or after dosing as they may reduce absorption. Grapefruit and grapefruit juice may increase cinacalcet levels; avoid concurrent use.
High-fiber foods (bran, oats) and certain foods containing pectin can reduce digoxin absorption; take Lanoxicaps on an empty stomach or at least 1 hour before or 2 hours after meals. St. John's Wort may decrease digoxin levels. Avoid licorice root, which can cause hypokalemia and increase toxicity. Consistent dietary potassium intake is important; avoid potassium supplements unless directed.
First trimester: Limited human data; animal studies show fetal harm at high doses (reduced fetal weight, skeletal variations). Second/third trimester: No adequate human studies; potential fetal/neonatal hypocalcemia due to maternal calcium-sensing receptor modulation. Risk cannot be excluded.
FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal bradycardia, low birth weight; therapeutic levels near toxic for fetus. Use only if maternal benefit outweighs risk.
No human data on excretion in breast milk; M/P ratio unknown. Potential for serious adverse reactions (e.g., hypocalcemia) in nursing infants; decision to discontinue breastfeeding or drug based on importance of drug to mother.
Digoxin is excreted into breast milk at low levels (M/P ratio ~0.6–0.9); infant exposure is subtherapeutic. Considered compatible with breastfeeding, but monitor infant for signs of digoxin toxicity (e.g., arrhythmias, nausea).
No specific dose adjustment guidelines; pharmacokinetics in pregnancy unknown. Monitor serum calcium frequently and adjust dose to maintain target calcium levels. Consider that volume of distribution and clearance may increase, potentially requiring higher doses.
Increased volume of distribution and renal clearance in pregnancy may lower digoxin levels; dose adjustment often needed in third trimester. Monitor levels frequently and increase dose if subtherapeutic. Postpartum, reduce dose as clearance normalizes.
SENSIPAR (cinacalcet) is a calcimimetic used for secondary hyperparathyroidism in CKD on dialysis and for hypercalcemia in parathyroid carcinoma. Monitor serum calcium closely; hypocalcemia is a common adverse effect. Do not initiate if serum calcium is below the lower limit of normal. Administer with food or shortly after a meal to increase absorption. Dose adjustments may be needed with moderate to severe hepatic impairment.
Lanoxicaps (digoxin) has a high bioavailability (90-100%) compared to standard digoxin tablets; adjust dose when switching formulations to avoid toxicity. Monitor renal function and electrolytes (especially potassium, magnesium, calcium) closely; hypokalemia increases digoxin toxicity risk. Digoxin toxicity can present with arrhythmias (e.g., bidirectional ventricular tachycardia, atrial tachycardia with block) and visual disturbances (yellow-green halos). Use digoxin-specific Fab fragments for life-threatening toxicity. Therapeutic drug monitoring: draw levels at least 6-8 hours after dose; target 0.5-0.9 ng/m L for heart failure, 0.8-2.0 ng/m L for atrial fibrillation.
Take this medication with food or right after a meal.,Do not split, crush, or chew tablets; swallow whole.,Report symptoms of low calcium: muscle cramps, numbness, tingling, or seizures.,Keep all lab appointments for calcium and PTH monitoring.,Avoid taking with other medications without consulting your doctor; some may interact.
Take exactly as prescribed; do not miss doses or double up. If a dose is missed, skip it unless close to next dose.,Do not switch between Lanoxicaps and standard digoxin tablets without your doctor's approval due to different absorption.,Report symptoms of toxicity: nausea, vomiting, diarrhea, confusion, visual changes (blurred vision, yellow-green halos), or irregular heartbeat.,Keep regular appointments for blood tests to monitor digoxin levels, kidney function, and electrolytes.,Avoid over-the-counter medications, especially antacids, kaolin-pectin, and some laxatives, which can affect absorption.,Maintain consistent dietary intake of potassium-rich foods (bananas, oranges) and avoid extreme changes in diet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SENSIPAR vs LANOXICAPS, answered by our medical review team.
SENSIPAR is a Calcimimetic that works by Calcimimetic agent that allosterically modulates the calcium-sensing receptor (Ca SR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.. LANOXICAPS is a Cardiac Glycoside that works by Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SENSIPAR and LANOXICAPS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SENSIPAR is: 30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target i PTH reduction.. The standard adult dose of LANOXICAPS is: 0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SENSIPAR and LANOXICAPS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SENSIPAR is classified as Category C. First trimester: Limited human data; animal studies show fetal harm at high doses (reduced fetal weight, skeletal variations). Second/third trimester: No adequate human studies; po. LANOXICAPS is classified as Category C. FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.